Frost & Sullivan Independent Equity Research

Cellect Biotechnology Ltd.: Exposure to the global stem cells industry

Company: Cellect Biotechnology Ltd.

Sector: Biotechnology

Report type: Quarterly Update

Published on: June 7th, 2017

View Fullscreen

Download full report

Cellect research articles:

Q2-2018 ·

Cellect. On track with its strategic plans; ApoGraft POC final results estimated to be published by mid-2019; sufficient cash to support clinical and preclinical trials; target price unchanged.

Cellect. On track with its strategic plans; successfully completed proof of concept for ApoTainerTM; sufficient cash to support clinical and preclinical trials; price target unchanged

All articles loaded

No more articles to load

INDEPENDENT EQUITY RESEARCH

Tel: +972(0)9.950.2888
Email: equity.research@frost.com

Contact us

Copyright © 2020 Frost & Sullivan. All Rights Reserved. Privacy Policy.

Accessibility by WAH